OXYCODONE MR APOTEX oxycodone hydrochloride 30mg modified release tablets blister pack

País: Australia

Idioma: inglés

Fuente: Department of Health (Therapeutic Goods Administration)

Ingredientes activos:

oxycodone hydrochloride, Quantity: 30 mg

Disponible desde:

Arrotex Pharmaceuticals Pty Ltd

Designación común internacional (DCI):

oxycodone hydrochloride

formulario farmacéutico:

Tablet, modified release

Composición:

Excipient Ingredients: colloidal anhydrous silica; hyprolose; iron oxide red; titanium dioxide; lactose; hypromellose; ethylcellulose; magnesium stearate; macrogol 8000; iron oxide black; iron oxide yellow

Vía de administración:

Oral

Unidades en paquete:

28, 20, 60

tipo de receta:

(S8) Controlled Drug

indicaciones terapéuticas:

OXYCODONE MR APOTEX modified release tablets are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive; and ? requires daily, continuous, long-term treatment. OXYCODONE MR APOTEX is not indicated for the use in chronic non-cancer pain other than in exceptional circumstances. OXYCODONE MR APOTEX is not indicated as an as-needed (PRN) analgesia.

Resumen del producto:

Visual Identification: Light brown, round, biconvex film-coated tablet, engraved 'APO' on one side, 'OCD' over '30' on the other side.; Container Type: Blister Pack; Container Material: PVC/PVDC/Al; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Estado de Autorización:

Licence status A

Fecha de autorización:

2014-11-21